Standard Chem & Pharm Co Ltd
TWSE:1720
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
60.9
78.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Standard Chem & Pharm Co Ltd
Standard Chem & Pharm Co Ltd
Cost of Revenue
Standard Chem & Pharm Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Cost of Revenue
-NT$3.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-8%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Cost of Revenue
-NT$4.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Cost of Revenue
-NT$2.6B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-2%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Cost of Revenue
-NT$2.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Cost of Revenue
-NT$904.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
1%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Cost of Revenue
-NT$7.7B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-24%
|
|
Standard Chem & Pharm Co Ltd
Glance View
Standard Chemical & Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese and western medicine, medicine raw materials, and health food. The company is headquartered in Tainan, Tainan. The Company’s products cover drugs for circulation systems, digest systems, respiratory systems, nervous systems and other diseases. Through its subsidiaries, the Company is also engaged in the sales of medical equipment, animal medicine, milk powder, cosmetics and others. The firm distributes its products both in domestic markets and overseas markets.
See Also
What is Standard Chem & Pharm Co Ltd's Cost of Revenue?
Cost of Revenue
-3.7B
TWD
Based on the financial report for Jun 30, 2024, Standard Chem & Pharm Co Ltd's Cost of Revenue amounts to -3.7B TWD.
What is Standard Chem & Pharm Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-8%
Over the last year, the Cost of Revenue growth was -7%. The average annual Cost of Revenue growth rates for Standard Chem & Pharm Co Ltd have been -15% over the past three years , -12% over the past five years , and -8% over the past ten years .
You don't have any saved screeners yet
